Niagen Bioscience (NAGE) Net Cash Flow (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Net Cash Flow of $1.8 million for Q1 2026, down 83.93% year-over-year from $11.0 million in Q1 2025, and up 236.71% quarter-over-quarter from $523000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Net Cash Flow (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Net Cash Flow for 14 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 83.93% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $10.9 million (down 61.02% YoY), while the FY2025 annual figure was $20.1 million, up 16.11% from the prior year.
- Net Cash Flow grew to $1.8 million in Q1 2026 per NAGE's latest filing, from $523000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.3 million in Q4 2024 and bottomed at -$7.2 million in Q1 2022.
- Historically, Net Cash Flow has averaged $2.3 million across 5 years, with a median of $1.8 million in 2026.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 125.81% — and 2025, when it soared 4465.0%.
- Niagen Bioscience's Net Cash Flow stood at $7.2 million in 2022, then sank by 92.31% to $552000.0 in 2023, then jumped by 2121.38% to $12.3 million in 2024, then slumped by 95.73% to $523000.0 in 2025, then surged by 236.71% to $1.8 million in 2026.
- Business Quant data shows NAGE's Net Cash Flow at $1.8 million in Q1 2026, $523000.0 in Q4 2025, and $3.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 191,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 191,000.00 |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 498,000.00 |
| Sep 30, 2025 | 3.82 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 10.96 Mn |
| Dec 31, 2024 | 12.26 Mn |
| Sep 30, 2024 | 4.51 Mn |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 552,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 2.70 Mn |
| Dec 31, 2022 | 7.18 Mn |
| Sep 30, 2022 | -3.81 Mn |
| Jun 30, 2022 | -3.92 Mn |
| Mar 31, 2022 | -7.23 Mn |
| Dec 31, 2021 | -4.88 Mn |
| Sep 30, 2021 | -5.68 Mn |